{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:44:37Z","timestamp":1771670677077,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004616","name":"Consiliul National al Cercetarii Stiintifice","doi-asserted-by":"publisher","award":["PC1-PN23080101"],"award-info":[{"award-number":["PC1-PN23080101"]}],"id":[{"id":"10.13039\/501100004616","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006595","name":"Executive Unit for Financing Higher Education Research Development and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Methods"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ymeth.2025.05.002","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:22:06Z","timestamp":1746724926000},"page":"13-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Electrochemical assay for the quantification of anticancer drugs and their inhibition mechanism"],"prefix":"10.1016","volume":"241","author":[{"given":"Ricardo Jose","family":"Branco Leote","sequence":"first","affiliation":[]},{"given":"Caroline G.","family":"Sanz","sequence":"additional","affiliation":[]},{"given":"Victor C.","family":"Diculescu","sequence":"additional","affiliation":[]},{"given":"Madalina Maria","family":"Barsan","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.ymeth.2025.05.002_b0005","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymeth.2025.05.002_b0010","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.2174\/1381612823666170720113216","article-title":"Protein Kinases as Tumor Biomarkers and Therapeutic Targets","volume":"23","author":"Quan","year":"2017","journal-title":"Curr Pharm Des."},{"key":"10.1016\/j.ymeth.2025.05.002_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/cells13191656","article-title":"Advances in cancer therapy: A comprehensive review of CDK and EGFR inhibitors","volume":"13","author":"Hawash","year":"2024","journal-title":"Cells."},{"key":"10.1016\/j.ymeth.2025.05.002_b0020","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov. 2021 2011"},{"key":"10.1016\/j.ymeth.2025.05.002_b0025","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol. Cancer."},{"issue":"13","key":"10.1016\/j.ymeth.2025.05.002_b0030","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20years (2001\u20132020)","volume":"131","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymeth.2025.05.002_b0035","doi-asserted-by":"crossref","unstructured":"Q. Zhang, P. Zheng, W. Zhu, D. Mu\u00f1oz-Torrero, B. De Pascual-Teresa, Research Progress of Small Molecule VEGFR\/c-Met Inhibitors as Anticancer Agents (2016\u2013Present), Mol. 2020, Vol. 25, Page 2666. 25 (2020) 2666. https:\/\/doi.org\/10.3390\/MOLECULES25112666.","DOI":"10.3390\/molecules25112666"},{"key":"10.1016\/j.ymeth.2025.05.002_b0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.drudis.2015.07.008","article-title":"Small-molecule kinase inhibitors: an analysis of FDA-approved drugs","volume":"21","author":"Wu","year":"2016","journal-title":"Drug Discov. Today."},{"key":"10.1016\/j.ymeth.2025.05.002_b0045","doi-asserted-by":"crossref","unstructured":"R. Roskoski, Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update, Pharmacol. Res. 103 (2016) 26\u201348. https:\/\/doi.org\/10.1016\/J.PHRS.2024.107059.","DOI":"10.1016\/j.phrs.2024.107059"},{"key":"10.1016\/j.ymeth.2025.05.002_b0050","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/cas.13211","article-title":"Enhanced expression of the M2 isoform of pyruvate kinase is involved in gastric cancer development by regulating cancer-specific metabolism","volume":"108","author":"Shiroki","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ymeth.2025.05.002_b0055","first-page":"5663","article-title":"The role of pyruvate kinase M2 in anticancer therapeutic treatments","volume":"18","author":"Su","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ymeth.2025.05.002_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00159","article-title":"Pyruvate kinase M2 and cancer: The role of PKM2 in promoting tumorigenesis","volume":"10","author":"Zahra","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymeth.2025.05.002_b0065","doi-asserted-by":"crossref","first-page":"15561","DOI":"10.1074\/jbc.M117.791343","article-title":"Pyruvate kinase M knockdown-induced signaling via AMP-activated protein kinase promotes mitochondrial biogenesis, autophagy, and cancer cell survival","volume":"292","author":"Prakasam","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymeth.2025.05.002_b0070","first-page":"1","article-title":"Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2","volume":"13","author":"Babu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ymeth.2025.05.002_b0075","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.bcp.2009.12.003","article-title":"Identification of small molecule inhibitors of pyruvate kinase M2","volume":"79","author":"Vander Heiden","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymeth.2025.05.002_b0080","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1039\/D1MD00045D","article-title":"Tumor pyruvate kinase M2 modulators: a comprehensive account of activators and inhibitors as anticancer agents","volume":"12","author":"Rathod","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ymeth.2025.05.002_b0085","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio799","article-title":"Rational design of inhibitors that bind to inactive kinase conformations","volume":"2","author":"Liu","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ymeth.2025.05.002_b0090","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.1021\/jm8010299","article-title":"Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states","volume":"51","author":"Kufareva","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ymeth.2025.05.002_b0095","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ymeth.2025.05.002_b0100","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/jm501603h","article-title":"Chem biol drug Des - 2009 - Zhou - structural analysis of DFG\u2010in and DFG\u2010out dual Src\u2010Abl inhibitors sharing a common vinyl.pdf","volume":"58","author":"Vijayan","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ymeth.2025.05.002_b0105","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1021\/jm901443h","article-title":"Through the \u201cgatekeeper door\u201d: Exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ymeth.2025.05.002_b0110","article-title":"Multidrug resistance in cancer: Understanding molecular mechanisms, immunoprevention and therapeutic approaches","volume":"12","author":"Bin Emran","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.ymeth.2025.05.002_b0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/154065804323056495","article-title":"High-throughput screening with quantitation of ATP consumption: a universal non-radioisotope, homogeneous assay for protein kinase","volume":"2","author":"Koresawa","year":"2004","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.ymeth.2025.05.002_b0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1087057107310806","article-title":"Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of Rho-kinase II (ROCK-II)","volume":"13","author":"Schr\u00f6ter","year":"2008","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.ymeth.2025.05.002_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2015.02.001","article-title":"An optimized lactate dehydrogenase release assay for screening of drug candidates in neuroscience","volume":"73","author":"Kaja","year":"2015","journal-title":"J. Pharmacol. Toxicol. Methods."},{"key":"10.1016\/j.ymeth.2025.05.002_b0130","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1570163813666160115125930","article-title":"Enzyme activity assays for protein kinases: Strategies to identify active substrates HHS public access","volume":"13","author":"Haubrich","year":"2016","journal-title":"Curr Drug Discov Technol."},{"key":"10.1016\/j.ymeth.2025.05.002_b0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bios.2018.02.034","article-title":"Electrochemical sensors and biosensors for the analysis of antineoplastic drugs","volume":"108","author":"Lima","year":"2018","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.ymeth.2025.05.002_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/s18010164","article-title":"Recent advances in electrochemical biosensors based on enzyme inhibition for clinical and pharmaceutical applications","volume":"18","author":"El Harrad","year":"2018","journal-title":"Sensors (Switzerland)."},{"key":"10.1016\/j.ymeth.2025.05.002_b0145","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1039\/D0AN02426K","article-title":"An antibody-based amperometric biosensor for 20S proteasome activity and inhibitor screening","volume":"146","author":"Barsan","year":"2021","journal-title":"Analyst"},{"key":"10.1016\/j.ymeth.2025.05.002_b0150","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.talanta.2019.02.052","article-title":"Electrochemical assay for 20S proteasome activity and inhibition with anti-cancer drugs","volume":"199","author":"Henriques de Jesus","year":"2019","journal-title":"Talanta"},{"key":"10.1016\/j.ymeth.2025.05.002_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2025.127886","article-title":"Electrochemical bienzimatic biosensor for pyruvate kinase activity evaluation and inhibitor screening","volume":"291","author":"Leote","year":"2025","journal-title":"Talanta"},{"key":"10.1016\/j.ymeth.2025.05.002_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.electacta.2021.139532","article-title":"Monodispersed nanoplatelets of samarium oxides for biosensing applications in biological fluids","volume":"402","author":"Leote","year":"2022","journal-title":"Electrochim. Acta."},{"key":"10.1016\/j.ymeth.2025.05.002_b0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12154-009-0029-3","article-title":"Hill coefficients, dose-response curves and allosteric mechanisms","volume":"3","author":"Prinz","year":"2010","journal-title":"J. Chem. Biol."},{"issue":"2","key":"10.1016\/j.ymeth.2025.05.002_b0170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12154-009-0023-9","article-title":"Measuring and interpreting the selectivity of protein kinase inhibitors","volume":"23","author":"Smyth","year":"2009","journal-title":"J. Chem. Biol."},{"key":"10.1016\/j.ymeth.2025.05.002_b0175","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1747-0285.2010.00972.x","article-title":"Chem Biol Drug Des - 2010 - Blat - Non\u2010Competitive Inhibition by Active Site Binders.pdf","volume":"75","author":"Blat","year":"2010","journal-title":"Chem. Biol. Drug Des."},{"issue":"n.d.","key":"10.1016\/j.ymeth.2025.05.002_b0180","article-title":"Novel strategy for hematoxylin electrochemical quantification based on screen printed electrode modified with graphene-CoS2 nanocomposite, J. Environ. Bioanal","volume":"1","author":"Author","year":"2025","journal-title":"Electrochem."},{"key":"10.1016\/j.ymeth.2025.05.002_b0185","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.5599\/admet.2593","article-title":"A new method for measuring dopamine in the presence of uric acid employing a carbon paste electrode modified with the UiO-66 metal organic framework-graphene oxide nanocomposite: Original scientific article","author":"Gatea","year":"2025","journal-title":"ADMET DMPK."},{"key":"10.1016\/j.ymeth.2025.05.002_b0190","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/0115734110270070231012123849","article-title":"A concise review on analytical methods for determination of nilotinib","volume":"19","author":"Khivansara","year":"2023","journal-title":"Curr. Anal. Chem."},{"key":"10.1016\/j.ymeth.2025.05.002_b0195","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s00604-016-1927-z","article-title":"Ultrasound assisted dispersive micro solid-phase extraction of four tyrosine kinase inhibitors from serum and cerebrospinal fluid by using magnetic nanoparticles coated with nickel-doped silica as an adsorbent","volume":"183","author":"Ghazaghi","year":"2016","journal-title":"Microchim. Acta."},{"key":"10.1016\/j.ymeth.2025.05.002_b0200","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s00216-020-02393-2","article-title":"Magnetic molecularly imprinted electrospun nanofibers for selective extraction of nilotinib from human serum","volume":"412","author":"Pirdadeh-Beiranvand","year":"2020","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ymeth.2025.05.002_b0205","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jchromb.2012.07.011","article-title":"Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry,","volume":"903","author":"Kralj","year":"2012","journal-title":"J. Chromatogr. B. Analyt. Technol. Biomed Life Sci."},{"key":"10.1016\/j.ymeth.2025.05.002_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2024.112220","article-title":"Development of HPLC-UV method for determination of Nilotinib in spiked human plasma with greenness assessment","volume":"207","author":"Smerikarova","year":"2024","journal-title":"Microchem. J."},{"key":"10.1016\/j.ymeth.2025.05.002_b0215","doi-asserted-by":"crossref","first-page":"8073","DOI":"10.1007\/s00216-020-02934-9","article-title":"Effect of monomer structure of anionic surfactant on voltammetric signals of an anticancer drug: rapid, simple, and sensitive electroanalysis of nilotinib in biological samples","volume":"412","author":"Sener","year":"2020","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ymeth.2025.05.002_b0220","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1021\/acsomega.4c05505","article-title":"Novel electrochemical approaches for anticancer drug monitoring: Application of CoS@nitrogen-doped amorphous porous carbon composite in nilotinib detection","volume":"10","author":"Y\u0131ld\u0131r","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.ymeth.2025.05.002_b0225","doi-asserted-by":"crossref","DOI":"10.1002\/open.202100261","article-title":"A DNA biosensor based on a raspberry-like hierarchical nano-structure for the determination of the anticancer drug nilotinib","volume":"11","author":"Moarefdoust","year":"2022","journal-title":"ChemistryOpen."},{"key":"10.1016\/j.ymeth.2025.05.002_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2021.339143","article-title":"A porous molecularly imprinted nanofilm for selective and sensitive sensing of an anticancer drug ruxolitinib","volume":"1187","author":"\u00c7orman","year":"2021","journal-title":"Anal. Chim. Acta."},{"key":"10.1016\/j.ymeth.2025.05.002_b0235","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/elan.202100625","article-title":"Electrochemical investigation of ruxolitinib: Sensitive voltammetric assay in drug product and human serum by using different solid electrodes","volume":"34","author":"Bilge","year":"2022","journal-title":"Electroanalysis"},{"key":"10.1016\/j.ymeth.2025.05.002_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.snb.2022.132127","article-title":"A novel electrochemical sensor based on magnetic Co3O4 nanoparticles\/carbon recycled from waste sponges for sensitive determination of anticancer drug ruxolitinib","volume":"367","author":"Bilge","year":"2022","journal-title":"Sensors Actuators B Chem."},{"key":"10.1016\/j.ymeth.2025.05.002_b0245","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1021\/acsabm.4c00186","article-title":"Electrochemical behavior of janus kinase inhibitor ruxolitinib at a taurine-electropolymerized carbon paste electrode: Insights into sensing mechanisms","volume":"7","author":"Subak","year":"2024","journal-title":"ACS Appl. Bio Mater."}],"container-title":["Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046202325001173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046202325001173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:54:27Z","timestamp":1762354467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1046202325001173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":49,"alternative-id":["S1046202325001173"],"URL":"https:\/\/doi.org\/10.1016\/j.ymeth.2025.05.002","relation":{},"ISSN":["1046-2023"],"issn-type":[{"value":"1046-2023","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Electrochemical assay for the quantification of anticancer drugs and their inhibition mechanism","name":"articletitle","label":"Article Title"},{"value":"Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymeth.2025.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}